InvestmentJul 1, 2026, 08:38 AM
Abivax Prices Upsized $800M Public Offering of ADSs
AI Summary
Abivax S.A. announced the pricing of its upsized public offering of 6,400,000 American Depositary Shares (ADSs) at $125.00 per ADS, a 2.39% premium to the three-day VWAP. The offering, which was increased from $600 million to $800 million, is expected to generate approximately $800 million in gross proceeds. These funds are projected to extend the company's cash runway into the second quarter of 2029, supporting the potential commercialization of obefazimod and continued clinical development. The underwriters also have an option to purchase additional ADSs, which could increase the total proceeds to $920 million.
Key Highlights
- Abivax priced an upsized public offering of 6,400,000 ADSs at $125.00 per ADS.
- The offering size increased from $600 million to $800 million.
- The offering price represents a 2.39% premium to the three-day volume-weighted average price.
- Expected gross proceeds are approximately $800 million (€702 million).
- Proceeds are anticipated to extend the company's cash runway into Q2 2029.
- Funds will support potential commercialization of obefazimod and clinical development.
- Underwriters have an option to purchase up to an additional 960,000 ADSs, potentially raising $920 million.
- The offering will result in a dilution of approximately 8.0% of the share capital.
Price Impact
More from ABVX